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Abstract
Background:  Maintaining quality of care while managing limited healthcare resources is an
ongoing challenge in healthcare. The objective of this study was to evaluate how the impact of drug
management programs is reported in the literature and to identify potentially existing quality
standards.
Methods: This analysis relates to the published research on the impact of drug management on
economic, clinical, or humanistic outcomes in managed care, indemnity insurance, VA, or Medicaid
in the USA published between 1996 and 2007. Included articles were systematically analyzed for
study objective, study endpoints, and drug management type. They were further categorized by
drug management tool, primary objective, and study endpoints.
Results: None of the 76 included publications assessed the overall quality of drug management
tools. The impact of 9 different drug management tools used alone or in combination was studied
in pharmacy claims, medical claims, electronic medical records or survey data from either patient,
plan or provider perspective using an average of 2.1 of 11 possible endpoints. A total of 68% of the
studies reported the impact on plan focused endpoints, while the clinical, the patient or the
provider perspective were studied to a much lower degree (45%, 42% and 12% of the studies).
Health outcomes were only accounted for in 9.2% of the studies.
Conclusion: Comprehensive assessment of quality considering plan, patient and clinical outcomes
is not yet applied. There is no defined quality standard. Benchmarks including health outcomes
should be determined and used to improve the overall clinical and economic effectiveness of drug
management programs.
Background
An ongoing challenge in the United States (USA) health-
care system that all stakeholders face is maintaining qual-
ity of care while managing limited healthcare resources.
Meanwhile, accreditation and professional organizations
facilitate provider and payer quality improvement efforts
by offering quality measurement and tracking initiatives.
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Some of the most widely recognized healthcare quality
measurement programs include accreditation and quality
reporting of the National Committee for Quality Assur-
ance (NCQA) which is based on the Healthcare Effective-
ness Data and Information Set (HEDIS) and the Joint
Commission on Accreditation of Healthcare Organiza-
tions (JCAHO) Performance Measurement initiatives. [1]
While measures of adherence to prescribing recommenda-
tions for specific diseases or conditions are incorporated
into HEDIS and JCAHO standards, they are not specifi-
cally designed to measure the quality of drug manage-
ment programs. Drug management programs and tools
are generally implemented by healthcare payers and
health systems to manage and control the use of prescrip-
tion drugs, with the ultimate goal to help ensure effective-
ness. This allows available resources to be used to deliver
desired health outcomes effectively. Thus, it is important
to monitor the impact of these programs to ensure that
drug management programs do not unintentionally lead
to negative patient outcomes as poor outcomes may in
turn increase overall medical costs.
Several efforts are underway to establish recognized qual-
ity measures for pharmaceutical care in various environ-
ments, including the payer/managed care setting. The
Academy of Managed Care Pharmacy (AMCP) Formulary
Submission Format is one initiative specifically focused
on drug management programs. The AMCP Format is a
guideline used by pharmaceutical manufactures for com-
piling clinical and economic data used by payers in mak-
ing evidence-based, value driven formulary decisions. [2]
Pharmaceutical components are included as part of a
more comprehensive quality program. One example is the
National Quality Forum (NQF), a multi-stakeholder
organization that is building consensus for measuring and
reporting healthcare quality across a variety of settings,
including therapeutic drug management. [3] In addition,
the National Business Coalition on Health (NBCH) has
created the eValue8 program which is used by business
coalitions to compare health plans across a variety of per-
formance measures, including pharmacy programs. [4]
Finally, URAC, which includes a wide range of stakehold-
ers (employers, consumers, pharmacy consultants, health
plans, independent retail pharmacy, pharmacy benefits
management (PBM) organizations, pharmacy profes-
sional organizations, labor, and large public purchasing
groups) has also devised a Pharmacy Benefit Management
Accreditation Format, which was made available in 2007
and aims to be a key benchmark for quality of care. [5]
These quality efforts are a start to measuring and evaluat-
ing quality for prescription drug management programs.
However, the stakeholders have not yet agreed on recog-
nized standards and benchmarks for determining how the
quality of drug management programs should be defined
and measured. Without such standards and transparent
performance reporting for drug management programs, it
is difficult for payers, providers, policymakers and
patients to establish or evaluate quality of drug manage-
ment programs.
Numerous reviews have been conducted to synthesize the
findings of drug management program research con-
ducted in the USA, including an assessment of economic
findings by Hadley et al. [6] and a recent review of the
association between cost sharing, medication utilization,
and outcomes found in the literature by Goldman et al.
[7] However, it appears that no published studies have
reviewed the methodological approaches taken in the US
to assess how program impact is measured across a range
of drug management tools to identify if evaluation trends
exist. Nor is there a review of how plans and researchers
use this data to assess program outcomes and quality.
Thus, the aim of this analysis was to evaluate how the
impact of drug management programs is quantified as
reported in the literature over the last 12 years and to iden-
tify whether predefined thresholds for quality are utilized
in these analyses. Such information will help identify
trends that can build towards a consensus for assessing
quality in payer-based drug management programs in the
US.
Methods
A librarian assisted search of the literature was conducted
of articles published in English from 1996 to 2007. The
time period of 12 years has been chosen to be able to
identify measurement processes related to drug manage-
ment tools currently utilized and to see potential changes
in the publications over time. The databases searched
include PubMed, International Pharmaceutical Abstracts
(IPA), CINAHL, and Business Source Premier. In addition,
meeting abstracts from the International Society of Phar-
macoeconomic and Outcomes Research (ISPOR) and
Academy of Managed Care Pharmacy (AMCP) were
reviewed. Search terms, which are listed in table 1, were
used alone and in combination to identify potential arti-
cles. In addition, the reference lists from key studies and
related review articles were reviewed to identify studies
not picked up in the automated search process.
Abstracts and articles generated from original research
studies, meta analyses, and other systematic reviews were
reviewed by a pharmacist and pharmacoeconomics out-
comes researcher for inclusion based on the following cri-
teria: (1) Studies must have been conducted in a managed
care, indemnity insurance, VA, or Medicaid setting in the
US; (2) Studies must have evaluated the impact of at leastBMC Health Services Research 2009, 9:38 http://www.biomedcentral.com/1472-6963/9/38
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one drug management tool including overall drug formu-
lary/preferred drug list, drug use review, copayment/cost-
sharing, prior authorization, coverage restrictions includ-
ing specific formulary restrictions, step edits, therapeutic
interchange, generic programs, and/or combinations of
the above; (3) Articles must have reported either proc-
esses, economic, clinical, or humanistic outcomes. If there
was ambiguity among the two reviewers, the study was
included or excluded based on a discussion and subse-
quent consensus. The results of the analysis were docu-
Table 1: Search terms for literature retrieval
Search Terms
Primary MeSH Headings
Insurance, Pharmaceutical services Drugs, non-prescription
Managed Care Programs Drugs, Generics
Pharmaceutical Preparations Prescriptions, Drug
Additional MeSH Headings
Formularies Total Quality Management
Pharmacy and Therapeutics Committee Outcome Assessment (Health Care)
Drug Utilization Review Cost Control
Deductibles and Coinsurance Cost Sharing
Reimbursement, Incentive Community Pharmacy Services
Additional MeSH Sub Headings
Classification Standards
Economics Statistics and numerical data
Methods Trends
Additional Free Text Search Terms
Drug Management Programs Step-edit
Drug Benefit/Pharmacy Benefit Therapeutic Substitution
Formularies Medication Therapy Management
Formulary Process Drug Therapy Management
*tier Copay (e.g. three-tier copay, four-tier copay) Pharmacy Cognitive Services
Formulary Restrictions Quality
Generic Drug Program/Mandatory Generic Prescribing Program Outcomes
Prior Authorization (Prescription Drug) Costs/Resources
Quantity Level Limits Patient Reported OutcomesBMC Health Services Research 2009, 9:38 http://www.biomedcentral.com/1472-6963/9/38
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mented in an Access database, which had been specifically
developed for the comparative analysis and evaluation in
this study. This database was used by both reviewers for
review and quality control.
All articles were systematically analyzed for the main
study objective, study endpoint parameters, the drug
management type, and other criteria. The review of the
studies revealed that the primary mechanisms of the drug
program management tools fell into three broad catego-
ries: (1) shifting 'financial responsibility to patient'
(including overall formulary programs, preferred drug
lists, and patient cost sharing measures), (2) 'limit or con-
trol access' (including specific formulary restrictions, prior
authorization, step edits, and quantity level limits), and
the (3) 'stimulation of switch to preferred agents' (includ-
ing therapeutic interchange, generic drug incentives, and
over-the-counter drug incentives). Similarly, the study
endpoints represented four different perspectives: (1)
'plan focus' (including plan cost and drug utilization), (2)
'patient focus' (including patient out-of-pocket cost and
patient satisfaction), (3) 'clinical focus'(including compli-
ance and persistence, likelihood of receiving treatment,
clinical outcome, and medical resource utilization), and
(4)'provider-focus' (including adherence to treatment
guidelines, prescription switching, and workload for pro-
vider). If a study evaluated two related drug program
tools, the study was categorized on the basis of each pro-
gram type. A small number of studies (n = 7; 9%) evalu-
ated more than two distinct programs (multiple drug
management type). Studies that evaluated multiple end-
points were included in each study endpoint category.
Results
The literature review identified 1099 potential articles.
Titles and abstracts of these articles were reviewed to
assess if the studies met the established inclusion criteria.
From this initial review, 193 articles were pulled for in-
depth review; 76 articles met all inclusion criteria and
were included in the assessment. These articles are listed
in Additional file 1[8-83]. An increase in the number of
studies can be seen throughout the time of our analysis;
there were three studies published before 1999, four in
1999–2000, thirteen in 2001–2002, twenty-four in 2003–
2004, and thirty-two in 2005–2007.
Primary drug management tools evaluated
None of the studies assessed quality related measures for
an overall drug management program. Rather, studies
examined the impact of 9 different drug management
tools alone or in combination.
A majority of the studies (43 studies; 57%) evaluated drug
management tools that shift financial responsibility for
non-preferred agents to patients through full or partial
cost sharing. Programs that drive use of preferred agents
by stimulating a switch in prescribing or utilization to pre-
ferred agents (8 studies; 14%) were the least common of
the three program types evaluated. The specific drug man-
agement tool most frequently evaluated was cost sharing
(41 studies; 54%). These studies assessed the impact of
multiple tier formularies or coinsurance programs (Figure
1). The least evaluated drug management program tools
were OTC coverage policies and overall preferred drug
list/formulary evaluations (each with 2 studies; 3%).
Study endpoints
Rx cost was the most frequently used endpoint (in 45 of
76 studies) followed by patient out-of-pocket cost (28 of
76), and medication adherence (24 of 76) (figure 2). Only
7 of the 76 studies, thus less than 10 percent, account for
a clinical or physiological disease related endpoint. An
average of 2.1 (+/- 1.1) endpoints were evaluated per
study. A majority of 49 studies (64%) looked at one or
two endpoints (Table 2).
The predominant study endpoint category utilized in eval-
uating the impact of drug management program tools was
plan focused (53/76 studies, 68%; Table 3). Within this
category, a plan drug cost endpoint was reported in 47/76
studies; 62%) followed by drug utilization (23/76 studies;
30%).
Clinical focused endpoints was the second highest end-
point category evaluated. A total of 35 of the 76 reviewed
studies assessed clinical endpoints (45%) including com-
pliance and persistence (24 studies), likelihood of receiv-
ing treatment (14 studies), and clinical outcomes (7
studies). Patient-focused endpoints was the third most
frequent endpoint category evaluated (33 of 76 studies;
42%). This category included patient out-of-pocket costs
(28 studies) and patient satisfaction (5 studies). Provider-
focused endpoints were evaluated in 8 studies (11%)
which included prescription switching (4 studies), guide-
line adherence (3 studies), and provider workload (2
studies).
Evaluations of drug management programs that shifted
financial responsibility to the patient (43 studies) pre-
dominately measured plan focused outcomes (30/43
studies; 70%) followed by patient-focused outcomes (27/
43 studies; 63%). Less than half evaluated a clinical
focused outcome (20/43 studies; 47%). A majority of
assessments of tools that limit or control access through
benefit restrictions (40 studies) included plan focused
outcomes (28/40 studies; 70%). Less than half evaluated
a patient-focused outcome (16/40 studies; 40%) or a clin-
ical focused outcome (15 of 40 studies; 38%). A similar
proportion of the 8 studies of drug management program
tools that stimulated a switch in prescribing or utilizationBMC Health Services Research 2009, 9:38 http://www.biomedcentral.com/1472-6963/9/38
Page 5 of 11
(page number not for citation purposes)
to preferred agents evaluated plan focused outcomes (6
studies; 75%) and patient-focused outcomes (3 studies;
38%), however none of these studies evaluated clinical
outcomes.
Across studies of drug management program tools, there
are examples where differences in conclusions may have
been caused by a lack of consensus on defining outcomes.
Two examples are discussed below.
A total of 14 of the 41 studies (34%) of drug management
program tools that involved cost sharing with the patient
such as tiered formularies and coinsurance, evaluated
treatment adherence as a study endpoint. Adherence was
measured by whether patients continued to take their
medication (persistence; 5 studies), by whether patients
took their medication as prescribed (compliance; 6 stud-
ies) or both (2 studies).
When persistence was evaluated, higher cost sharing had
no effect (5 studies)[15,23,56,59,79] or mixed effects (1
study). [63], with only one study finding that higher cost
sharing negatively impacted medication continuation.
[39] When compliance was evaluated the opposite was
identified. Seven studies found that compliance decreased
with higher cost sharing [15,29,33,47,54,75,78], and two
studies found that compliance increased with lower cost
sharing. [13,50] The second example relates to studies
that evaluated step edit programs by the impact on plan
costs. [58,66,80,82] The studies differed by whether
administrative costs were considered in addition to drug
costs. When only drug costs were considered, all four stud-
ies concluded that step edits drove cost savings for the
plan. However, one study also included administrative
costs, and in this case the authors concluded that step
edits did not deliver a cost savings to the health plan. [66]
Benchmarks
The published evaluations of drug management programs
generally did not utilize pre-defined goals for assessing
the quality of the program evaluated. In one exception,
Monane et al studied the impact of a pharmacist interven-
tion program in which physicians were contacted regard-
ing possible medication related problems in the elderly.
Drug Management Type Figure 1
Drug Management Type. Number of studies analyzing the impact of each drug management tool (total = 76).BMC Health Services Research 2009, 9:38 http://www.biomedcentral.com/1472-6963/9/38
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[55] This study identified a prescribing change benchmark
of 2% as the minimum target, which reflects the average
rate of prescribing change in physician practice overall.
Discussion
This analysis evaluated studies that quantified the impact
of drug management program tools on health plans and
patients. The purpose of this study was to identify how
management programs are evaluated and whether prede-
fined thresholds for quality are utilized.
Overall, studies of drug management programs are rela-
tively limited in scope. While 11 endpoints were used
across the literature most studies focused on one or two
endpoints (64% of the studies). The predominant per-
spective was that of the plan, with 53 (70%) of the studies
analyzing a plan focused outcome. This trend reflects the
fact that most drug management tool evaluations are con-
ducted and published by health plans, which would
clearly have a vested interest in measuring how drug man-
agement program tools impact the plan financially.
Study Endpoints Figure 2
Study Endpoints. Number of studies analyzing specific endpoints.
Table 2: Endpoint breadth used for different drug management tool categories
N u m b e r  o f  E n d p o i n t s 1234 5 N u m b e r  o f  S t u d i e s A v e r a g e  N o .  o f  E n d p o i n t s S t .  D e v
Drug Management Tool Category
Financial responsibility to patient 16 8 13 4 2 43 2.3 1.2
Limit access to non-preferred agents 17 12 8 2 1 40 2.0 1.0
S t i m u l a t e  s w i t c h  t o  p r e f e r r e d  a g e n t s 6200 0 8 1 . 3 0 . 5
All Drug Management Programs 29 20 18 6 3 2.1 1.1
Analysis by number of endpoints included in the studies in each drug management tool category (n = 76)BMC Health Services Research 2009, 9:38 http://www.biomedcentral.com/1472-6963/9/38
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Drug management programs also impact patients finan-
cially or by limiting the range of drugs that they can access
with their pharmacy benefit. However, just less than half
of the identified studies included a patient-focused out-
come relating to out of pocket costs, or patient satisfaction
(n = 33; 43%). Similarly, less than half of the identified
studies included clinical endpoints (n = 35; 46%). Thus,
most drug management tool evaluations are not yet meas-
uring the full impact to plans and patients in terms of total
healthcare costs and clinical outcomes. [84] Austvoll-
Dahlgren et al. performed an international systematic
review of the effects of coverage caps and co-payments on
rational drug use and concluded that introducing or
increasing co-payments reduced drug use and saved plan
drug expenditures. However, the authors point out a lack
of discussion in these articles on the intensity of the caps
and copayments, and similar to this review, that there was
little assessment of their impact on health outcomes or
continuation of treatment.
In our analysis, studies of drug management programs
that shift costs to patients tended to be more comprehen-
sive. However, just over half of these studies included a
patient-focused or clinical endpoint in addition to a plan-
focused endpoint. A move towards more comprehensive
quality analyses is not yet seen with evaluations of other
drug management tool categories. Notably, only a third of
program evaluations of drug management tools that limit
or control access through benefit restrictions included
patient-focused or clinical outcomes. Program evalua-
tions of tools that enforce or encourage switching to pre-
ferred agents exhibited the highest proportion of studies
that included a plan-focused outcome. While the propor-
tion that included a patient-focused outcome was similar
to the other drug management tool categories, none of
these studies included a clinical outcome.
Provider-focused endpoints were the least evaluated, with
the greatest proportion of evaluations that included a pro-
vider-focused endpoint were those of cost shifting drug
management program tools. This is an interesting obser-
vation as benefit design limits may mandate adherence to
prescribing of preferred agents. Such programs could also
result in no medication being prescribed, thus provider
behavior endpoints measuring adherence with treatment
guidelines is warranted. However, only 6 of the 40 studies
on limiting access to non-preferred drugs evaluated pre-
scriber behavior, and of those only 2 assessed adherence
with treatment guidelines.
It was interesting that evaluations of drug management
programs that shift costs to patients were more likely to
evaluate patient-focused and clinical endpoints than eval-
uations of programs that limit or control access through
benefit restrictions or by stimulating a switch in prescrib-
ing or utilization to preferred agents. This trend may be
related to concerns that shifting costs to patients may have
the unintended consequence of causing patients to not
take medications as prescribed and therefore may result in
negative clinical or humanistic outcomes. Hence, this
group of studies reflects the point of view of a different set
of stakeholders. The considerations of patient and clinical
endpoints in addition to plan endpoints may reflect an
evolution of drug management program evaluations.
However, only less than 10% of the studies included a dis-
ease related clinical or physiological outcome. Consider-
ing, that the improvement of the clinical or physiological
level should be at the core of healthcare, there appears to
be a large gap in studying the impact of drug management
programs. A study by Hodgkin et al. on the impact of three
tiered formularies on antidepressant utilization and
expenditures notes that the health economic conse-
quences and quality impact of multi-tiered formularies
may depend on the therapeutic area. Non-differential cost
shifting to patients may limit individual therapy adapta-
Table 3: Relation between Drug Management Tool Objective and Study Endpoints
Drug Management Program
Categories
N Plan focus Patient Focus Clinical Focus Provider Focus
n 76 53 33 35 9
% 70% 43% 46% 5%
Financial responsibility to patient n 43 30 27 20 2
% 70% 63% 47% 5%
Limit access to non-preferred agents n 40 28 13 15 6
% 70% 33% 38% 15%
Stimulate switch to preferred agents n 86 3 0 1
% 75% 38% 0% 13%
Number of Studies by Drug Management Tool Category and Study Endpoint Type: The percentages relate to the number of studies in that drug 
management program category. Studies with several endpoints can be in multiple endpoint categories, studies comparing different drug 
management programs can be in multiple drug management program categories.BMC Health Services Research 2009, 9:38 http://www.biomedcentral.com/1472-6963/9/38
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tions. [85] These authors, therefore also suggest tracking
the effects of three-tier programs on patient adherence,
quality of care, and clinical and economic outcomes.
In addition to forming a consensus on which endpoints
are most appropriate to evaluate for specific drug manage-
ment tools, it is also important to obtain and maintain
agreement on how specific endpoints are evaluated. This
study defined endpoints in fairly specific terms with the
purpose of categorization. Even with such specific end-
point definitions two examples of endpoint disparity were
evident: in (1) medication adherence (medication com-
pliance and persistence) as an endpoint in cost shifting
drug management programs and (2) plan costs in evalua-
tions of step edit programs. In these cases, differences in
measurement approaches led to different conclusions.
Thus, to ensure that plans, payers, and patients can com-
pare and contrast the quality of different or similar pro-
grams there a need to reach consensus on what is being
measured as well as how the endpoints are measured.
In addition, a conspicuously absent element of drug man-
agement program studies was the lack of predefined tar-
gets or recognized quality benchmarks. While studies
were qualified in terms of endpoint measures, such as 'did
or did not reduce costs', 'did or did not impact medication
compliance', these evaluations tended to describe out-
comes without specifying the ideal target a priori and
what would constitute an acceptable range of outcomes.
Only one study identified a prescribing change bench-
mark/goal which was based on an estimate of the average
percentage of prescribing that differs in a prescriber from
one year to the next. However, this article failed to justify
the selected 2% benchmark versus a higher rate that may
have been more indicative of prescribing changes in the
presence of known clinical risks. Thus, while any article
utilizing a benchmark should be commended, it is equally
important that the benchmark be justified for the given
setting and program objective.
Overall, this analysis has identified that, currently, there is
a lack of consistency in how drug management program
tools are evaluated. Furthermore, drug management tool
evaluations tend to fall short of comprehensives assess-
ments and they do not identify and apply comparative
benchmarks. Drug management program tools often con-
sidered costs to the health plan or patient costs or satisfac-
tion. However, a minority of the evaluations incorporated
an overall assessment of clinical outcomes or medical uti-
lization to ensure that programs support the efficient and
effective use of health plan resources. In other words, few
drug management program tool assessments measure
value as defined by the relation between quality of care
and efficiency of care. [86] Our observation is confirmed
by the findings of Lu et al who reviewed the impact of
interventions targeting drug use in the US managed care
setting. [87] Despite evidence for the effectiveness of sev-
eral strategies in changing drug use in the managed care
environment, the most studies did not provide evidence
for the cost-effectiveness of the interventions. Similarly,
Ovsag et al. raise the issue of compromising long term
quality of care and overall economic impact for the advan-
tage of expected short-term cost savings in the context of
preferred drug lists in the Medicaid environment. [88]
In April 2002, the Academy of Managed Care Pharmacy
(AMCP) introduced the Pharmacy's Framework for Drug
Therapy Management in the 21st Century. In this, the
working group of more than 100 drug therapy specialists
agreed on the following measurements for improving
healthcare quality: (a) a better patient outcome at the
same cost, (b) the same patient outcome at lower cost, (c)
a better patient outcome at lower cost, or (d) a signifi-
cantly better patient outcome at moderately higher cost.
[89] Consequently, any form of quality assurance has to
integrate cost and patient outcome monitoring and will
not be complete without integrating multiple perspec-
tives.
While this analysis begins to identify an information void
regarding the quality assessment of management pro-
grams, the analysis has several limitations that warrant
mention. First, the published literature is likely to lag real-
world activities related to the quality assessment of drug
management programs. Thus, the published literature
may not yet reflect the cutting edge or detect emerging
trends in the quality assessment of drug management pro-
grams. Continued publication of these evaluations should
be highly encouraged to share best practices and facilitate
consensus on quality assessment approaches for drug
management program tools.
Additional limitations arise from the study design, includ-
ing the somewhat subjective categorization of drug man-
agement tool types and study endpoints. Different
categorization approaches may have modified specific
study findings and conclusions. However, it is unlikely
that different means to describing program evaluations
would have changed the primary conclusions regarding
the current lack of consensus on program tool evaluations
and lack of benchmarks for determining the quality of
drug management program tools as is also confirmed by
other upcoming publications in this context. [84,87-89]
In this review, we have analyzed the methods used by
researchers to study the impact of drug formulary manage-
ment tools and whether there is any indication that qual-
ity assessment standards have emerged. To illustrate the
risk of inconsistency in the quality assessment of drug
management program tools we selected two examples ofBMC Health Services Research 2009, 9:38 http://www.biomedcentral.com/1472-6963/9/38
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how different methods of endpoint evaluation clearly
impacted conclusions. While the methodological ques-
tion is the focus of this paper, it will also be important to
understand the actual impact of the diverse drug formu-
lary management programs. Such a review should be
much more in depth than the isolated examples used here
and thus, it is planned as an additional extended step of
this study.
Conclusion
In summary, the literature evaluating the impact of drug
management programs has revealed that trends in how to
measure the impact and quality of drug management pro-
grams are starting to emerge. However, consensus is not
yet building uniformly across types of drug management
programs, and a comprehensive assessment of quality
considering plan, patient and clinical focused outcomes is
not yet applied. Furthermore, there is no evidence in the
literature that researchers and health plans have identified
and recognized benchmarks or goals that programs
should be striving to achieve to ensure that efforts to man-
age drug benefit resources are not compromising patient
outcomes. More than 90% of studies do not even consider
clinical or physiological disease related criteria. Future
research should concentrate on how to efficiently use
resources to achieve the best possible health outcome.
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